148 related articles for article (PubMed ID: 1331449)
1. Orally active, nonpeptide oxytocin antagonists.
Evans BE; Leighton JL; Rittle KE; Gilbert KF; Lundell GF; Gould NP; Hobbs DW; DiPardo RM; Veber DF; Pettibone DJ
J Med Chem; 1992 Oct; 35(21):3919-27. PubMed ID: 1331449
[TBL] [Abstract][Full Text] [Related]
2. 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.
Williams PD; Clineschmidt BV; Erb JM; Freidinger RM; Guidotti MT; Lis EV; Pawluczyk JM; Pettibone DJ; Reiss DR; Veber DF
J Med Chem; 1995 Nov; 38(23):4634-6. PubMed ID: 7473590
[No Abstract] [Full Text] [Related]
3. Nanomolar-affinity, non-peptide oxytocin receptor antagonists.
Evans BE; Lundell GF; Gilbert KF; Bock MG; Rittle KE; Carroll LA; Williams PD; Pawluczyk JM; Leighton JL; Young MB
J Med Chem; 1993 Dec; 36(25):3993-4005. PubMed ID: 8258821
[TBL] [Abstract][Full Text] [Related]
4. Role of oxytocin in the initiation of term and preterm labor in rats: changes in oxytocin receptor density and plasma oxytocin concentration and the effect of an oxytocin antagonist, L-366,509.
Kobayashi M; Akahane M; Minami K; Moro M; Ajisawa Y; Inoue Y; Kawarabayashi T
Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):621-7. PubMed ID: 10076138
[TBL] [Abstract][Full Text] [Related]
5. 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.
Williams PD; Anderson PS; Ball RG; Bock MG; Carroll L; Chiu SH; Clineschmidt BV; Culberson JC; Erb JM; Evans BE
J Med Chem; 1994 Mar; 37(5):565-71. PubMed ID: 8126695
[TBL] [Abstract][Full Text] [Related]
6. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
Chan WY; Wo NC; Cheng LL; Manning M
J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
[TBL] [Abstract][Full Text] [Related]
7. Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.
Kuo MS; Bock MG; Freidinger RM; Guidotti MT; Lis EV; Pawluczyk JM; Perlow DS; Pettibone DJ; Quigley AG; Reiss DR; Williams PD; Woyden CJ
Bioorg Med Chem Lett; 1998 Nov; 8(21):3081-6. PubMed ID: 9873680
[TBL] [Abstract][Full Text] [Related]
8. Progress in the development of oxytocin antagonists for use in preterm labor.
Pettibone DJ; Guidotti M; Harrell CM; Jasper JR; Lis EV; O'Brien JA; Reiss DR; Woyden CJ; Bock MG; Evans BE
Adv Exp Med Biol; 1995; 395():601-12. PubMed ID: 8714024
[TBL] [Abstract][Full Text] [Related]
9. Identification of an orally active, nonpeptidyl oxytocin antagonist.
Pettibone DJ; Clineschmidt BV; Kishel MT; Lis EV; Reiss DR; Woyden CJ; Evans BE; Freidinger RM; Veber DF; Cook MJ
J Pharmacol Exp Ther; 1993 Jan; 264(1):308-14. PubMed ID: 8423533
[TBL] [Abstract][Full Text] [Related]
10. The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor.
Borthwick AD; Liddle J
Med Res Rev; 2011 Jul; 31(4):576-604. PubMed ID: 20027670
[TBL] [Abstract][Full Text] [Related]
11. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea.
Akerlund M; Melin P; Maggi M
Adv Exp Med Biol; 1995; 395():595-600. PubMed ID: 8714023
[TBL] [Abstract][Full Text] [Related]
12. Receptors for and myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy: effects of the oxytocin antagonist atosiban.
Bossmar T; Akerlund M; Fantoni G; Szamatowicz J; Melin P; Maggi M
Am J Obstet Gynecol; 1994 Dec; 171(6):1634-42. PubMed ID: 7802081
[TBL] [Abstract][Full Text] [Related]
13. Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
Tsukada J; Tahara A; Tomura Y; Wada Ki ; Kusayama T; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
Br J Pharmacol; 2001 Jul; 133(5):746-54. PubMed ID: 11429400
[TBL] [Abstract][Full Text] [Related]
14. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.
Manning M; Misicka A; Olma A; Bankowski K; Stoev S; Chini B; Durroux T; Mouillac B; Corbani M; Guillon G
J Neuroendocrinol; 2012 Apr; 24(4):609-28. PubMed ID: 22375852
[TBL] [Abstract][Full Text] [Related]
15. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
[TBL] [Abstract][Full Text] [Related]
16. A structurally unique, potent, and selective oxytocin antagonist derived from Streptomyces silvensis.
Pettibone DJ; Clineschmidt BV; Anderson PS; Freidinger RM; Lundell GF; Koupal LR; Schwartz CD; Williamson JM; Goetz MA; Hensens OD
Endocrinology; 1989 Jul; 125(1):217-22. PubMed ID: 2544402
[TBL] [Abstract][Full Text] [Related]
17. Non-peptide oxytocin agonists.
Pitt GR; Batt AR; Haigh RM; Penson AM; Robson PA; Rooker DP; Tartar AL; Trim JE; Yea CM; Roe MB
Bioorg Med Chem Lett; 2004 Sep; 14(17):4585-9. PubMed ID: 15357997
[TBL] [Abstract][Full Text] [Related]
18. A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors.
Lemaire W; O'Brien JA; Burno M; Chaudhary AG; Dean DC; Williams PD; Freidinger RM; Pettibone DJ; Williams DL
Eur J Pharmacol; 2002 Aug; 450(1):19-28. PubMed ID: 12176104
[TBL] [Abstract][Full Text] [Related]
19. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
20. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist.
Yamamura Y; Ogawa H; Chihara T; Kondo K; Onogawa T; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
Science; 1991 Apr; 252(5005):572-4. PubMed ID: 1850553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
